ALK-Positive NSCLC: Alecensa Phase III Efficacy and Safety Data

Phase III Trial Results

• February 18, 2016

Chugai Pharmaceutical announced Phase III trial results evaluating alectinib (Alecensa) in untreated ALK-positive non-small cell lung cancer. The trial demonstrated superior efficacy with no safety concerns, leading to early termination.

Clinical Context

Alectinib represents an ALK tyrosine kinase inhibitor developed for ALK-positive NSCLC treatment. Phase III trial results support efficacy and tolerability in first-line ALK-positive disease.

Trial Outcomes

Phase III trial demonstrated:

• Superior clinical efficacy outcomes
• Favorable safety and tolerability profile
• No novel or unexpected adverse events
• Early termination due to positive efficacy signals

Clinical Significance

Alectinib efficacy in Phase III trial validates ALK inhibition as standard first-line approach for ALK-positive NSCLC, with favorable benefit-risk profile supporting regulatory approval and clinical adoption.

Data Source

http://www.chugai-pharm.co.jp/

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4